{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:31:48Z","timestamp":1787142708851,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A case in which cefiderocol was used for the treatment of ventriculitis caused by difficult-to-treat resistance in Pseudomonas aeruginosa (DTR-PA) is reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A 56-year-old female with a relevant past medical history significant for type 2 diabetes mellitus was admitted to the intensive care unit for an acute large intraparenchymal hemorrhage. Despite numerous attempts at neurosurgical interventions and procedures (eg, hematoma evacuation, external ventricular drain placement, ventriculoperitoneal shunt placement), the patient developed worsening hydrocephalus. While dependent on mechanical ventilation, she developed multiple episodes of ventilator-associated pneumonia (VAP) secondary to pansusceptible Pseudomonas aeruginosa infection treated with courses of cefepime and meropenem. Eventually, the patient developed DTR-PA VAP and was treated with ceftolozane\/tazobactam. On day 124, she was unresponsive and febrile, and cerebrospinal fluid (CSF) culture grew DTR-PA. Although antimicrobial susceptibility testing indicated that the P. aeruginosa isolate was susceptible to ceftolozane\/tazobactam at a minimum inhibitory concentration of 4 \u00b5g\/mL, the clinical decision to utilize cefiderocol instead was made. Despite use of cefiderocol for a 3-week course, neurologic examination findings remained poor. After multiple repeat CSF cultures suggesting no growth, 3 weeks after completion of therapy CSF culture grew DTR-PA again, with a similar susceptibility pattern. Thus, the patient was restarted on an additional 9 weeks of cefiderocol. After completion of a total of 12 weeks of cefiderocol therapy, repeat CSF cultures demonstrated microbiological eradication and the patient remained clinically stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This patient case demonstrates cefiderocol's potential clinical utility for the treatment of DTR-PA ventriculitis, providing real-world context in an area with limited clinical data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag108","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:41:05Z","timestamp":1775216465000},"page":"e623-e628","source":"Crossref","is-referenced-by-count":0,"title":["Cefiderocol for the treatment of difficult-to-treat resistance in\n                    <i>Pseudomonas aeruginosa<\/i>\n                    ventriculitis"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-3664","authenticated-orcid":false,"given":"Kelvin","family":"Gandhi","sequence":"first","affiliation":[{"name":"AdventHealth Daytona Beach , Daytona Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrene N","family":"Molineros","sequence":"additional","affiliation":[{"name":"AdventHealth Daytona Beach , Daytona Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erinc","family":"Akture","sequence":"additional","affiliation":[{"name":"AdventHealth Daytona Beach , Daytona Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Crossman","sequence":"additional","affiliation":[{"name":"AdventHealth Daytona Beach , Daytona Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Khan","sequence":"additional","affiliation":[{"name":"AdventHealth Daytona Beach , Daytona Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"2026081907561570900_zxag108-B1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: a review in serious gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"2026081907561570900_zxag108-B2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2026081907561570900_zxag108-B3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2026081907561570900_zxag108-B4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138161213804070311","article-title":"Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa","volume":"19","author":"Wolter","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2026081907561570900_zxag108-B5","doi-asserted-by":"crossref","first-page":"ofab216","DOI":"10.1093\/ofid\/ofab216","article-title":"Ventriculitis: a severe complication of central nervous system infections","volume":"8","author":"Luque-Paz","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2026081907561570900_zxag108-B6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"2026081907561570900_zxag108-B7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/AAC.41.5.987","article-title":"Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients","volume":"41","author":"Nau","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081907561570900_zxag108-B8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Luque-Paz","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"2026081907561570900_zxag108-B9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ofid\/ofab466.1300","article-title":"Evaluation of penetration of cefiderocol into cerebrospinal fluid using a rat meningitis model","volume":"8","author":"Takemura","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2026081907561570900_zxag108-B10","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2026081907561570900_zxag108-B11","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/jac\/dkad277","article-title":"Plasmatic and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa meningoencephalitis","volume":"78","author":"Funiciello","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026081907561570900_zxag108-B12","doi-asserted-by":"crossref","first-page":"dlac004.043","DOI":"10.1093\/jacamr\/dlac004.043","article-title":"P44 nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol","volume":"4","author":"Stevenson","year":"2022","journal-title":"JAC Antimicrobial Resist"},{"issue":"8","key":"2026081907561570900_zxag108-B13","doi-asserted-by":"crossref","first-page":"ofac391","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa Ventriculitis using cefiderocol: a case report and literature review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2026081907561570900_zxag108-B14","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026081907561570900_zxag108-B15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jgar.2022.11.019","article-title":"Intravenous cefiderocol for neurosurgical meningitis from an extensively drug-resistant New-Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa strain","volume":"32","author":"Stevenson","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"2026081907561570900_zxag108-B16","first-page":"819","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026081907561570900_zxag108-B17","doi-asserted-by":"publisher","first-page":"e01698","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal fluid penetration of ceftolozane-tazobactam in critically ill patients with an indwelling external ventricular drain","volume":"65","author":"Sime","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2026081907561570900_zxag108-B18","doi-asserted-by":"crossref","first-page":"ofaa549","DOI":"10.1093\/ofid\/ofaa549","article-title":"Plasma and cerebrospinal fluid therapeutic drug monitoring of ceftolozane and tazobactam during treatment of multidrug-resistant Pseudomonas aeruginosa meningitis","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2026081907561570900_zxag108-B19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/antibiotics13050453","article-title":"Role of cefiderocol in multidrug-resistant gram negative central nervous system infections: real life experience and state-of-the art","volume":"13","author":"Sollima","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2026081907561570900_zxag108-B20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01998-20","article-title":"A systematic review of studies reporting antibiotic pharmacokinetic data in the cerebrospinal fluid of critically ill patients with uninflamed meninges","volume":"65","author":"Kumta","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026081907561570900_zxag108-B21","first-page":"454","article-title":"Treatment with cefiderocol in K. pneumoniae KPC nosocomial external ventricular drainage meningitis: a brief report","volume":"30","author":"Colombo","year":"2022","journal-title":"Infez Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag108\/67786814\/zxag108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/17\/e623\/67786814\/zxag108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/17\/e623\/67786814\/zxag108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:56:28Z","timestamp":1787140588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/17\/e623\/8586798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":21,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,4,4]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag108","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,1]]},"published":{"date-parts":[[2026,4,4]]}}}